Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Xhance® (fluticasone propionate) – New indication
March 15, 2024 - OptiNose announced the FDA approval of Xhance (fluticasone propionate), for the treatment of chronic rhinosinusitis without nasal polyps (CRSsNP) in adults.
